SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-17-302235
Filing Date
2017-10-03
Accepted
2017-10-03 16:31:05
Documents
3
Period of Report
2017-09-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d453096d8k.htm 8-K 27196
2 EX-99.1 d453096dex991.htm EX-99.1 20676
3 GRAPHIC g453096g74y83.gif GRAPHIC 8302
  Complete submission text file 0001193125-17-302235.txt   60685
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

IRS No.: 273521219 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37587 | Film No.: 171118328
SIC: 2834 Pharmaceutical Preparations